Cutting-edge MRD detection for every point of patient care
Leading cancer centers standardize on clonoSEQ®, using it to precisely identify minimal residual disease (MRD) at the DNA sequence level. When integrated into routine clinical practice, clonoSEQ is an essential part of advancing patient care in lymphoid malignancies.
Applying clonoSEQ to the clinical setting
Learn how clinicians at top cancer centers incorporate clonoSEQ in routine clinical practice to make treatment decisions and inform patient care.
Ultra-sensitive MRD detection
The FDA-cleared clonoSEQ Assay is a highly sensitive, specific, and standardized method for detecting and monitoring MRD in patients with multiple myeloma, B-cell acute lymphoblastic leukemia (ALL), and chronic lymphocytic leukemia (CLL).[1,2] MRD refers to the small number of cancer cells that can remain in a patient’s body during and after treatment and may eventually cause recurrence of the disease.
clonoSEQ leverages the power of next-generation sequencing (NGS) and offers an accurate and reliable way to assess how disease burden changes over time in response to treatment or during remission.[1,2]
clonoSEQ can help clinicians:
Peer-reviewed clinical data
clonoSEQ predicts PFS in peripheral blood and bone marrow samples
clonoSEQ identifies more MRD-positive patients than other methods
clonoSEQ predicts outcomes in pre- and post-transplant settings
clonoSEQ predicts outcomes pre-transplant
What gets measured gets managed®
News and updates
Adaptive Biotechnologies Included in More than 20 Abstracts at ASCO and EHA 2021 Highlighting Expanding Use Cases for MRD Testing with the clonoSEQ® Assay in Blood Cancer Patients
Studies demonstrate value of MRD in novel treatment settings including CAR T cell therapy and in a growing range of patient types, including Non-Hodgkin’s Lymphoma.
Adaptive Biotechnologies Announces New Clinical Data Demonstrating Impact of clonoSEQ® Assay on Patients with Blood Cancers at the 62nd ASH Annual Meeting
Adaptive Biotechnologies Receives Expanded FDA Clearance for the clonoSEQ® Assay to Assess Minimal Residual Disease (MRD) in Patients with Chronic Lymphocytic Leukemia.
What We’re Sharing Follow Us
https://t.co/acmAhTJHM1 MM pt & fndr of @myelomacrowd, @AhlstromJenny, discusses new #myeloma treatments & importance of #MRD. clonoSEQ is FDA-cleared to assess MRD in pts with CLL, MM, or B-ALL. For important info. incl. sample types & test limitations: https://t.co/sE39cuHWh3 pic.twitter.com/TqvukaILJn
— clonoSEQ (@clonoSEQ) May 13, 2021
This page is intended for a US-based audience.
clonoSEQ® is available as an FDA-cleared in vitro diagnostic (IVD) test service provided by Adaptive Biotechnologies to detect minimal residual disease (MRD) in bone marrow from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (B-ALL) and blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). Additionally, clonoSEQ is available for use in other lymphoid cancers and specimen types as a CLIA validated laboratory developed test (LDT). IGHV testing is available as a CLIA-validated LDT and has not been cleared or approved by the FDA. For important information about the FDA-cleared uses of clonoSEQ including test limitations, please visit clonoSEQ.com/technical-summary.
- clonoSEQ®. [technical summary]. Seattle, WA. Adaptive Biotechnologies; 2020. https://www.clonoseq.com/technical-summary/.
- Ching T, et al. BMC Cancer. 2020;20:612.
- Pulsipher M, et al. Blood. 2015;125(22):3501-3508.